



June 16, 2026

To,  
**Listing Compliance Department**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai - 400 001.  
**Scrip Code: 543280**

**Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051.  
**Scrip Symbol: NAZARA**

**Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”) – Update on infusion of funds into Nazara Technologies UK Limited, a wholly owned subsidiary of the Company.**

Dear Sir / Madam,

This is with reference to our disclosure dated March 18, 2026, made pursuant to Regulation 30 read with Schedule III of Listing Regulations regarding, *inter alia*, proposed infusion of funds not exceeding USD 100.3 million by the Company into Nazara Technologies UK Limited, a wholly owned subsidiary of the Company ('Nazara UK'), in one or more tranches and subject to compliance with the applicable laws, by way of: (a) subscribing to its equity shares for an amount not exceeding USD 40.1 million; and (b) grant of a loan for an amount not exceeding USD 60.2 million.

We wish to inform you that the indicative timeline for infusion of funds into Nazara UK has been extended to August 14, 2026.

You are requested to take the above disclosure on record.

Thanking you,

Yours faithfully,  
For **Nazara Technologies Limited**

**Arun Bhandari**  
**Company Secretary and Compliance Officer**

**Nazara Technologies Limited**

CIN: L72900MH1999PLC122970  
📍 11th Floor, Avighna House, Dr. A.B. Road,  
Worli, Mumbai – 400018.  
☎ 91-22-40330800 / 22810303 / 22813030  
✉ info@nazara.com  
🌐 www.nazara.com

